MMP-19 (catalytic domain) (human), (recombinant)

MMP-19 is expressed widely, and degrades aggrecan, fibronectin, type I gelatin, and basement membrane components such as laminin, nidogen, and type IV collagen. It is involved in angiogenesis, cancer, rheumatoid arthritis, multiple sclerosis, and psoriasis.

Ordering Information


Order Online »

BML-SE561-0010

10µg

Manuals, SDS & CofA

View Online »



SDS-PAGE Analysis: Lane 1: MW Marker, Lane 2: 0.5 µg of Purified MMP-19 (catalytic domain) (human) (rec.) Prod. No. BML-SE561.

Handling & Storage

Use/Stability When stored under the recommended conditions, this enzyme is stable at the

concentration supplied, in its current storage buffer. Procedures such as dilution

followed by refreezing could lead to loss of activity.

Handling Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -80°C.

Long Term Storage -80°C

Shipping Dry Ice

Regulatory Status RUO - Research Use Only

Product Details

Activity Preincubation of MMP-19 catalytic domain at 1.9µM with

> the broad-spectrum inhibitor GM6001 (Prod No. BML-El300) at 100nM for 30 minutes only weakly inhibits

enzymatic activity (27%).

Alternative Name Matrix metalloproteinase 19, RASI

Application Notes Useful tool to study enzyme kinetics, cleave target

substrates, and screen for inhibitors.

Formulation Liquid. In 25mM NaBorate, pH 9.3, containing 5mM CaCl₂,

20μM ZnCl₂, 0.05% Brij-35 and 20% glycerol.

MW 19.2 kDa

Purity ≥95% (SDS-PAGE)

Purified by multi-step chromatography. **Purity Detail**

Recombinant MMP-19 corresponding to aa Leu⁹⁹-Ser²⁵⁹ Sequence

(NM 002429), which comprises the catalytic domain of

human MMP-19, with a C-terminal purification tag.

Source Produced in E.coli. Active recombinant MMP-19.

≥ 0.40U/µg. One U=100 pmol/min at 37°C using the Specific Activity

colorimetric thiopeptolide Ac-Pro-Leu-Gly-S-Leu-Leu-Gly-

OEt (100µM; Prod. No. BML-P125) as substrate.

UniProt ID Q99542

Last modified: May 29, 2024



eu@enzolifesciences.com